© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
In November 2021, the FDA approved pafolacianine for use as an imaging drug for identifying lesions in patients with ovarian cancer during surgery.
December 21st 2021, 3:00pm
November 29th 2021, 9:00pm
Imaging drug imaging drug pafolacianine was approved by the FDA to detect ovarian cancer lesions in patients during surgery.
January 30th 2022